<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524731</url>
  </required_header>
  <id_info>
    <org_study_id>11-149-SDR</org_study_id>
    <nct_id>NCT01524731</nct_id>
  </id_info>
  <brief_title>The Effect of Prophylactic Antiemetic Dexamethasone on Plasma Cortisol Levels</brief_title>
  <official_title>The Effect of Prophylactic Antiemetic Dexamethasone on Plasma Cortisol Levels After Gynecologic Laparotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Li Pi Shan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexamethasone is a synthetic corticosteroid that has been proven to be effective and&#xD;
      relatively safe for the prophylaxis of the postoperative nausea and vomiting (PONV).&#xD;
&#xD;
      However, little is known about its effect on the hypothalamic-pituitary-adrenal (HPA) axis&#xD;
      after surgery. The investigators hypothesize that it will inhibit the normal physiologic HPA&#xD;
      surge and reduce cortisol levels post-operatively ia a dose-dependant fashion. To answer this&#xD;
      question, the investigators will conduct a randomized, double-blinded placebo-controlled&#xD;
      trial with two different doses of dexamethasone in women undergoing elective gynecologic&#xD;
      laparotomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      The investigators hypothesize that preoperative administration of intravenous dexamethasone&#xD;
      in non-cancer gynecologic laparotomy will decrease postoperative cortisol levels in a&#xD;
      dose-dependent fashion.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To compare the post-operative plasma cortisol and glucose level in patients receiving various&#xD;
      single doses of dexamethasone versus placebo at the start of gynecologic laparotomy.&#xD;
&#xD;
      To assess the dose-dependent effect of dexamethasone on postoperative pain, nausea and&#xD;
      vomiting in this particular context.&#xD;
&#xD;
      To assess the dose-dependent effect of dexamethasone on length of hospital stay.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      This will be a prospective, randomised, double-blinded trial with two intervention arms and a&#xD;
      placebo-control arm conducted at the Royal Victoria Hospital of the McGill University Health&#xD;
      Center, Montreal, Canada.&#xD;
&#xD;
      Patients eligible to participate in the study based on inclusion and exclusion criteria will&#xD;
      be approached in the preoperative anesthesia clinic (at least one week before the scheduled&#xD;
      operation) and some patients will be recruited on the day of surgery hours before in the&#xD;
      waiting room by a study personnel who will not be involved in the patient care the day of the&#xD;
      surgery. After addressing the patient's questions and concerns, informed consent will be&#xD;
      obtained. The patient, the investigators and the anesthesiologist in charge of the patient&#xD;
      will be blinded to group allocation until completion of the study.&#xD;
&#xD;
      After patient recruitment, an intravenous line will be placed inside the operating room.&#xD;
      Blood will simultaneously be drawn for a baseline plasma cortisol levels. The patients will&#xD;
      receive a single IV bolus dose of dexamethasone 4mg, 8mg or an IV normal saline placebo&#xD;
      (based on group allocation by randomization) immediately after induction of anesthesia 8.&#xD;
      Anesthetic premedication will comprise of 1mg of midazolam. Induction will be performed using&#xD;
      2-3 mg/kg propofol, 2-3 mcg/kg fentanyl, 0.5-1.0 mg/kg rocuronium. Anesthetic maintenance&#xD;
      will be performed through an endotracheal tube using desflurane at a minimum of 1 MAC in an&#xD;
      equal air/oxygen mixture. Endtidal carbon dioxide tension will be maintained at 40 mmHg using&#xD;
      the appropriate ventilator adjustments. Fluid management consists of crystalloid boluses of&#xD;
      20 mg/kg to replace fasting losses, colloid and blood products as necessary according to the&#xD;
      surgical losses. Neostigmine and glycopyrrolate reversal will be used if no train of four&#xD;
      twitch exists. Ondansetron 4 mg will be given to all patients prior to tracheal extubation.&#xD;
&#xD;
      In the postoperative anesthesia care unit, dimenhydrinate 25-50 mg, prochlorperazine 10 mg&#xD;
      will be used should nausea, vomiting, or retching occur. Pain will be controlled by rectal&#xD;
      acetaminophen 325mg-1.3 g. Patient controlled analgesia fentanyl will be administered to all&#xD;
      patients at a lockout interval of 7 minutes. In the gynaecological ward, dimenhydrinate will&#xD;
      be used to control nausea and vomiting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative cortisol level</measure>
    <time_frame>24h post-operation</time_frame>
    <description>The primary outcome is the plasma cortisol level at 24h post-operation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma cortisol</measure>
    <time_frame>72 hours post-operatively</time_frame>
    <description>Plasma cortisol levels at 6, 48 and 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative nausea and vomiting scale</measure>
    <time_frame>72 hours post-operatively</time_frame>
    <description>Post operative nausea and vomiting at 6, 24, 48 and 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative pain score</measure>
    <time_frame>72 hours post operatively</time_frame>
    <description>postoperative pain scores at 6, 24, 48 and 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose level</measure>
    <time_frame>72 hours post-operatively</time_frame>
    <description>blood glucose levels at 6, 24, 48 and 72 hours</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg dexamethasone group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 8 mg group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>4 mg</description>
    <arm_group_label>4 mg dexamethasone</arm_group_label>
    <other_name>4 mg dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>8 mg</description>
    <arm_group_label>Dexamethasone 8 mg</arm_group_label>
    <other_name>8 mg dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between 18 and 80 years-old scheduled for non-oncologic gynecologic laparotomy,&#xD;
             including fibroid myomectomy, hysterectomy and endometrioma resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Communication barrier rendering informed consent inadequate&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Chronic or acute renal failure&#xD;
&#xD;
          -  Chronic or acute hepatic failure&#xD;
&#xD;
          -  History of chronic opioid use&#xD;
&#xD;
          -  History of corticosteroid use more than 3 weeks in the last 6 months (inhaled, oral or&#xD;
             intravenous)&#xD;
&#xD;
          -  History of disorders of the hypothalamus, pituitary gland and/or adrenal glands&#xD;
&#xD;
          -  History of depression and/or bipolar disorder&#xD;
&#xD;
          -  History of allergy or sensitivity to dexamethasone or any medication used in the&#xD;
             standardised anesthetic care&#xD;
&#xD;
          -  American Society of Anesthesiologists Physical Status class of 3 and above.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William K. Li Pi Shan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McGill University Health Centre-Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <last_update_submitted>September 2, 2014</last_update_submitted>
  <last_update_submitted_qc>September 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>William Li Pi Shan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

